ArticleDigestive diseases and sciences2025

Glucagon-Like Peptide-1 Receptor Agonist Therapy Does Not Increase Gastrointestinal Adverse Events in Patients with Inflammatory Bowel Disease.

Jonathan Weng et al.PubMed ↗Publisher ↗

No numbers read from the abstract.